CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Innoviva Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Innoviva Inc
1350 OLD BAYSHORE HIGHWAY, SUITE 400
Phone: (650) 238-9600p:650 238-9600 BURLINGAME, CA  94010  United States Ticker: INVAINVA
Business Summary
Innoviva, Inc. is a diversified holding company with a portfolio of royalties and other healthcare assets. The Company's royalty portfolio consists of respiratory assets partnered with Glaxo Group Limited (GSK), including RELVAR/BREO ELLIPTA (fluticasone furoate/vilanterol, FF/VI) and ANORO ELLIPTA (umeclidinium bromide/vilanterol, UMEC/VI). Under the Long-Acting Beta2 Agonist (LABA) Collaboration Agreement, the Company is entitled to receive royalties from GSK on sales of RELVAR/BREO ELLIPTA. The Company's products include GIAPREZA and XERAVA. GIAPREZA (angiotensin II) injection is approved by the United States Food and Drug Administration (FDA) as a vasoconstrictor indicated to increase blood pressure in adults with septic or other distributive shock. XERAV (eravacycline) for injection is approved by the United States FDA and Singapore Health Sciences Authority (HSA) as a tetracycline class antibacterial indicated for the treatment of complicated intra-abdominal infections (cIAI).

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
9/30/202412/31/2023YesYes-YesYes

Industries
SIC Code Description
2834 Pharmaceutical preparations
6794 Patent owners and lessors
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman of the Board Mark A.Dipaolo 53 5/1/2023 2/1/2018
Chief Executive Officer PavelRaifeld 41 5/20/2020 5/20/2020
Chief Financial Officer StephenBasso 58 8/21/2023 8/21/2023
5 additional Officers and Directors records available in full report.

Subsidiaries
Business Name Address City State/Province Country
La Jolla Pharmaceutical Company 201 Jones Road, Suite 400 WALTHAM MA United States
Entasis Therapeutics Holdings Inc 35 Gatehouse Drive WALTHAM MA United States
Entasis Therapeutics Inc Boston BioHub, 35 Gatehouse Drive WALTHAM MA United States
Tetraphase Pharmaceuticals, Inc. 480 Arsenal Way Watertown MA United States
ADVANCED MEDICINE EAST INC 8 CLARKE DR CRANBURY NJ

Business Names
Business Name
Advanced Medicine East, Inc
Entasis Therapeutics (Ireland) Limited
Entasis Therapeutics Holdings Inc.
19 additional Business Names available in full report.

General Information
Number of Employees: 112 (As of 12/31/2023)
Outstanding Shares: 62,601,081 (As of 10/31/2024)
Shareholders: 63
Stock Exchange: NASD
Federal Tax Id: 943265960
Fax Number: (302) 655-5049


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Monday, December 2, 2024